These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17194390)

  • 1. [Lipid alterations and cardiovascular risk associated with antiretroviral therapy].
    Masiá-Canuto M; Bernal-Morell E; Gutiérrez-Rodero F
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):637-48. PubMed ID: 17194390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid metabolism in treated HIV Infection.
    Dubé MP; Cadden JJ
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):429-42. PubMed ID: 21663837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lipid disorders in patients with HIV-induced diseases].
    Chanu B; Valensi P
    Presse Med; 2005 Sep; 34(15):1087-94. PubMed ID: 16334888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class of antiretroviral drugs and the risk of myocardial infarction.
    ; Friis-Møller N; Reiss P; Sabin CA; Weber R; Monforte Ad; El-Sadr W; Thiébaut R; De Wit S; Kirk O; Fontas E; Law MG; Phillips A; Lundgren JD
    N Engl J Med; 2007 Apr; 356(17):1723-35. PubMed ID: 17460226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk and dyslipidemia among persons living with HIV: a review.
    Maggi P; Di Biagio A; Rusconi S; Cicalini S; D'Abbraccio M; d'Ettorre G; Martinelli C; Nunnari G; Sighinolfi L; Spagnuolo V; Squillace N
    BMC Infect Dis; 2017 Aug; 17(1):551. PubMed ID: 28793863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiovascular risk factors associated with antiretroviral therapy].
    Pérez-Camacho I; Camacho A; Torre-Cisneros J; Rivero A
    Enferm Infecc Microbiol Clin; 2009 Sep; 27 Suppl 1():24-32. PubMed ID: 20172412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.
    Rimland D; Guest JL; Hernández I; Del Rio C; Le NA; Brown WV
    HIV Med; 2005 Sep; 6(5):326-33. PubMed ID: 16156880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.
    Bain AM; White EA; Rutherford WS; Rahman AP; Busti AJ
    Pharmacotherapy; 2008 Jul; 28(7):932-8. PubMed ID: 18576908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nurse practitioner's role in managing dyslipidemia and other cardiovascular risk factors in HIV-infected patients: impact of antiretroviral therapy.
    Willard S
    J Assoc Nurses AIDS Care; 2006; 17(1):7-17. PubMed ID: 16686080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of statins in the setting of HIV infection.
    Eckard AR; McComsey GA
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):305-12. PubMed ID: 26126687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy.
    Rodríguez-Gallego E; Gómez J; Domingo P; Ferrando-Martínez S; Peraire J; Viladés C; Veloso S; López-Dupla M; Beltrán-Debón R; Alba V; Vargas M; Castellano AJ; Leal M; Pacheco YM; Ruiz-Mateos E; Gutiérrez F; Vidal F; Rull A;
    Atherosclerosis; 2018 Jun; 273():28-36. PubMed ID: 29677628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents.
    The RESPOND Study Group
    AIDS; 2021 May; 35(6):869-882. PubMed ID: 33443370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical management considerations for dyslipidemia in HIV-infected individuals.
    Kirchner JT
    Postgrad Med; 2012 Jan; 124(1):31-40. PubMed ID: 22314112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dyslipidemia in HIV-infected individuals.
    Sprinz E; Lazzaretti RK; Kuhmmer R; Ribeiro JP
    Braz J Infect Dis; 2010; 14(6):575-88. PubMed ID: 21340298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges.
    Ahmed MH; Al-Atta A; Hamad MA
    Expert Opin Pharmacother; 2012 Sep; 13(13):1901-9. PubMed ID: 22770622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.